Development of versatile fractionation method of human atrial myocytes from Tet-1 stabilized-human iPS cells

• Project/Area Number: 26293313
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Partial Multi-year Fund
• Section: 一般
• Research Field: Cardiovascular surgery
• Research Institution: Saitama Medical University
• Principal Investigator: Senbonmatsu Takaaki 埼玉医科大学, 医学部, 教授 (70216563)
• Co-Investigator(Kenkyū-buntansha): 井口 篤志 埼玉医科大学, 医学部, 教授 (90222851) ; 加藤 英政 愛媛大学, 医学(系)研究科(研究院), 准教授 (50292123)
• Project Period (FY): 2014-04-01 – 2018-03-31
• Project Status: Completed (Fiscal Year 2017)
• Budget Amount: ¥16,120,000 (Direct Cost: ¥12,400,000、Indirect Cost: ¥3,720,000); Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000); Fiscal Year 2016: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000); Fiscal Year 2015: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000); Fiscal Year 2014: ¥7,670,000 (Direct Cost: ¥5,900,000、Indirect Cost: ¥1,770,000)
• Keywords: iPS細胞 / 心不全 / 再生 / 患者初代培養 / 心筋細胞 / ヒトiPS細胞 / 心房筋細胞 / 心筋細胞群誘導 / 間葉系細胞 / 心房利尿ペプチド / ANP分泌細胞

Outline of Final Research Achievements

For development of a versatile human induced pluripotent stem cells (hiPSc) method, HiPSc induction was performed with patient’s primary somatic cells that are fibroblasts from the skin and the heart. However, induction efficacy of hiPSc was very low compared with that of commercial available human fibroblasts. The fibroblasts from the remainder tissue after surgery highly expressedα－SMA（smooth muscle actin）, so-called these are myofibroblats. Although using the myofibroblasts, it was very hard to create hiPSc, an initial medium without TGF-βfor hiPSc induction led to development of hiPSc successfully. But it was still low efficacy. Using the hiPSc from the myofibroblasts, we achieved the cardiomyocytes differentiation.